CAJ | 학술논문

目的探讨乌司他丁在急性非ST段抬高型心肌梗死后心力衰竭中的应用价值.方法 66例急性非ST段抬高型心肌梗死后心力衰竭患者随机分为两组,对照组30例,观察组36例,对照组采用常规治疗,观察组在常规治疗的基础上加用乌司他丁,共治疗14 d.观察左室射血分数(LVEF)、尿量、血浆超敏C-反应蛋白(hsCRP)、尿酸(UA)和氨基末端脑钠肽前体(NT-proBNP),并且观察心脏事件的发生情况.结果两组患者治疗后LVEF均有明显改善,并且观察组改善优于对照组,差异有统计学意义(P＜0.05).两组患者治疗后尿量均有明显增加,并且观察组多于对照组,差异有统计学意义(P＜0.05).两组患者血浆hs-CRP、UA和NT-proBNP在治疗后均有明显降低,并且观察组低于对照组,差异有统计学意义(P＜0.05).对照组心脏事件发生9例,占30％;观察组心脏事件发生3例,占8.3％,两组比较差异有统计学意义(P＜0.01).结论乌司他丁可明显改善急性非ST段抬高型心肌梗死后心力衰竭病情.
목적 탐토오사타정재급성비ST단태고형심기경사후심력쇠갈중적응용개치.방법 66례급성비ST단태고형심기경사후심력쇠갈환자수궤분위량조,대조조30례,관찰조36례,대조조채용상규치료,관찰조재상규치료적기출상가용오사타정,공치료14 d.관찰좌실사혈분수(LVEF)、뇨량、혈장초민C-반응단백(hsCRP)、뇨산(UA)화안기말단뇌납태전체(NT-proBNP),병차관찰심장사건적발생정황.결과 량조환자치료후LVEF균유명현개선,병차관찰조개선우우대조조,차이유통계학의의(P＜0.05).량조환자치료후뇨량균유명현증가,병차관찰조다우대조조,차이유통계학의의(P＜0.05).량조환자혈장hs-CRP、UA화NT-proBNP재치료후균유명현강저,병차관찰조저우대조조,차이유통계학의의(P＜0.05).대조조심장사건발생9례,점30％;관찰조심장사건발생3례,점8.3％,량조비교차이유통계학의의(P＜0.01).결론 오사타정가명현개선급성비ST단태고형심기경사후심력쇠갈병정.
Objective To study the value of ulinastatin on patients with heart failure after acute non-ST-segment elevation myocardial infarction(NSTEMI).Methods Sixty-six patients with heart failure after acute NSTEMI were randomly divided into ontrol group (30 cases) and observation group (36 cases).Patients in the control group were treated with the conventional treatment,and patients in the observation group were treated with the conventional treatment plus ulinastatin.They were treated for 14 days.The levels of left ventricular ejection fraction(LVEF),urine,plasma high-sensitivity C-reactive protein (hs-CRP),uric acid (UA) and N-amino-terminal pro-brain natriuretic peptide (NTproBNP) were observed,and the occurrence of cardiac events were observed.Results LVEF in patients were significantly improved after treatment,and the difference was significant (P ＜ 0.05).The urine output increased obviously in observation group than that in the control group,the difference was statistically significant(P ＜ 0.05).The plsmas hs-CRP,UA and NT-proBNP levels in the observation group were significantly lower after treatment in the observationgroup than those in the control group,the differences were statistically significant(P ＜ 0.05).There were 9 cases(30％) of cardiac events in the control group and 3 cases (8.3 ％) in the observation group,there were significant differences between the two groups(P ＜ 0.01).Conclusions Ulinastatin can significantly improve the heart failure after acute NSTEMI.